# MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

> **NCT02269319** · PHASE2 · COMPLETED · sponsor: **MicuRx** · enrollment: 120 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** MRX-I
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT02269319
- **Lead sponsor:** MicuRx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-08
- **Final completion:** 2015-09
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269319, "MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02269319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*